Edition:
United States

Merck & Co Inc (MRK.N)

MRK.N on New York Stock Exchange

63.18USD
24 Mar 2017
Change (% chg)

$-0.10 (-0.16%)
Prev Close
$63.28
Open
$63.16
Day's High
$63.53
Day's Low
$62.87
Volume
3,263,308
Avg. Vol
3,279,322
52-wk High
$66.80
52-wk Low
$52.46

MRK.N

Chart for MRK.N

About

Merck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company's Pharmaceutical segment includes... (more)

Overall

Beta: 0.85
Market Cap(Mil.): $173,465.20
Shares Outstanding(Mil.): 2,745.57
Dividend: 0.47
Yield (%): 2.98

Financials

  MRK.N Industry Sector
P/E (TTM): 45.04 29.17 29.94
EPS (TTM): 1.40 -- --
ROI: 4.91 13.48 13.01
ROE: 9.25 14.39 14.16

BRIEF-European Medicines Agency's CHMP recommends approval of Merck's keytruda

* European Medicines Agency's CHMP recommends approval of Merck's keytruda (pembrolizumab) for the treatment of patients with relapsed or refractory classical hodgkin lymphoma

Mar 24 2017

Merck employee's relative settles SEC insider trading case

A Pennsylvania foot doctor has agreed to pay nearly $123,000 to resolve charges he traded on inside information he received from a relative working at Merck & Co Inc about a planned merger, U.S. securities regulators said on Thursday.

Mar 23 2017

U.S. appeals court revives Fosamax warning claims against Merck

A federal appeals court on Wednesday revived hundreds of claims by plaintiffs who accused Merck & Co of failing to adequately warn about the risks of thigh bone fractures associated with its osteoporosis drug Fosamax.

Mar 22 2017

Merck must face renewed Fosamax warning claims: U.S. appeals court

A federal appeals court on Wednesday revived claims by several hundred plaintiffs who accused Merck & Co of failing to adequately warn about the risks of thigh bone fractures associated with its osteoporosis drug Fosamax.

Mar 22 2017

UPDATE 3-Merck must face renewed Fosamax warning claims -U.S. appeals court

March 22 A federal appeals court on Wednesday revived claims by several hundred plaintiffs who accused Merck & Co of failing to adequately warn about the risks of thigh bone fractures associated with its osteoporosis drug Fosamax.

Mar 22 2017

U.S. appeals court revives Fosamax warning claims against Merck

March 22 A federal appeals court on Wednesday revived hundreds of claims by plaintiffs who accused Merck & Co of failing to adequately warn about the risks of thigh bone fractures associated with its osteoporosis drug Fosamax.

Mar 22 2017

BRIEF-U.S. appeals court revives claims against Merck over Fosamax

March 22 U.S. Appeals Court Revives Hundreds Of Claims Alleging Merck & Co

Mar 22 2017

Merck's Keytruda wins FDA nod for treating blood cancer

Merck & Co Inc said on Tuesday it had got a nod from the U.S. Food and Drug Administration for its already-approved immunotherapy drug Keytruda as a treatment for a type of blood cancer.

Mar 14 2017

Merck's Keytruda wins FDA nod for treating blood cancer

March 14 Merck & Co Inc said on Tuesday it had got a nod from the U.S. Food and Drug Administration for its already-approved immunotherapy drug Keytruda as a treatment for a type of blood cancer.

Mar 14 2017

BRIEF-Merck says FDA approves keytruda for treatment of patients with refractory classical hodgkin lymphoma

* FDA approves Merck's Keytruda® (pembrolizumab) for adult and pediatric patients with classical hodgkin lymphoma (chl) refractory to treatment, or who have relapsed after three or more prior lines of therapy

Mar 14 2017

More From Around the Web

Competitors

Earnings vs. Estimates